Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 2;27(1):14.
doi: 10.1007/s11883-024-01253-z.

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 European Society of Cardiology Congress

Vashma Junaid  1 , Abdul Mannan Khan Minhas  2 , Maha Inam  3 , Colin Hinkamp  4 , Khawaja M Talha  5 , Chelsea Meloche  4 , Sana Sheikh  6 , Adeel Khoja  6   7 , Chayakrit Krittanawong  8 , Elizabeth M Vaughan  2   9 , Dinesh K Kalra  10 , Leandro Slipczuk  11 , Salim S Virani  6   12   13
Affiliations
Review

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 European Society of Cardiology Congress

Vashma Junaid et al. Curr Atheroscler Rep. .

Abstract

Purpose of review: To summarize selected late-breaking science on cardiovascular disease (CVD) prevention presented at the 2024 European Society of Cardiology (ESC) Congress.

Recent findings: Key studies from the 2024 ESC Congress highlight advances in (CVD) management. Apolipoprotein A-1 infusions reduced risk in acute myocardial infarction patients with high LDL cholesterol. Plozasiran cut triglycerides and apolipoprotein C-III levels, lowering pancreatitis risk. A 14-year study linked smoking among youth to cardiac abnormalities. Baseline hsCRP, LDL-C, and Lp(a) were strong predictors of 30-year outcomes in women. Alternative LDL-lowering strategies matched high-intensity statins in effectiveness of LDL-C lowering and reduced diabetes risk. Early combination lipid lowering therapy improved outcomes post-myocardial infarction. Nordic and Mediterranean diets were linked to lower atherosclerotic CVD risk. The findings from the 2024 ESC Congress highlight significant advancements in CVD prevention, including novel lipid-lowering therapies, biomarker-based risk prediction, and lifestyle interventions. These studies underscore the importance of early and personalized treatment strategies to mitigate long-term cardiovascular risk.

Keywords: Apolipoprotein A-1; CACS; CVD Prevention; ESC; LDL-c; Lp(a); MACE; Plozasiran.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: Dr. Virani is a Section Editor for the Springer journals Current Atherosclerosis Reports and Current Cardiology Reports. Dr. Slipczuk has received consulting honorarium from Amgen and Philips, participated in the advisory board for Bristol-Myers-Squib, and serves as site PI for V-INITIATE and Ocean(a) trials. The other authors declare that they have no conflict of interest. Financial Declarations. Dr. Virani is supported by the Department of Veterans Affairs, NIH, NIHR UK, Tahir, and Jooma Family Foundation. Dr. Slipczuk has received institutional grants from Amgen and Philips. Human and Animal Rights and Informed Consent: This article does not contain any studies with human participants or animals performed by any of the authors.

References

    1. Gupta K, Rawlley B, Meloche C, Minhas AMK, Hermel M, Slipczuk L, et al. Highlights of Cardiovascular Disease Prevention studies presented at the 2024 American College of Cardiology Conference. Curr Atheroscler Rep. 2024;26(8):367–81. - DOI - PubMed
    1. Gupta K, Hinkamp C, Andrews T, Meloche C, Minhas AMK, Slipczuk L, et al. Highlights of Cardiovascular Disease Prevention studies presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023;25(12):965–78. - DOI - PubMed
    1. Gibson CM, Duffy D, Korjian S, Bahit MC, Chi G, Alexander JH, et al. Apolipoprotein A1 infusions and Cardiovascular outcomes after Acute myocardial infarction. N Engl J Med. 2024;390(17):1560–71. - DOI - PubMed
    1. Apolipoprotein A-I, Infusions, and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels. : The AEGIS-II Trial | European Heart Journal | Oxford Academic [Internet]. [cited 2024 Sep 12]. https://academic.oup.com/eurheartj/advance-article/doi/ https://doi.org/10.1093/eurheartj/ehae614/7745365
    1. Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A et al. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. N Engl J Med [Internet]. [cited 2024 Sep 12];0(0). https://www.nejm.org/doi/full/ https://doi.org/10.1056/NEJMoa2409368

LinkOut - more resources